BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation
NYSE:BHC • CA0717341071
Current stock price
5.6 USD
+0.21 (+3.9%)
At close:
5.6 USD
0 (0%)
After Hours:
This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BHC Profitability Analysis
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- In the past 5 years BHC reported 4 times negative net income.
- BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- BHC's Return On Assets of 0.60% is amongst the best of the industry. BHC outperforms 80.31% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 7.78%, BHC belongs to the top of the industry, outperforming 86.53% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for BHC is significantly below the industry average of 13.06%.
- The 3 year average ROIC (6.89%) for BHC is below the current ROIC(7.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- BHC's Profit Margin of 1.53% is amongst the best of the industry. BHC outperforms 80.31% of its industry peers.
- The Operating Margin of BHC (21.28%) is better than 88.60% of its industry peers.
- BHC's Operating Margin has improved in the last couple of years.
- The Gross Margin of BHC (70.65%) is better than 77.72% of its industry peers.
- BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. BHC Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
- The number of shares outstanding for BHC has been increased compared to 1 year ago.
- BHC has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for BHC has been reduced compared to a year ago.
2.2 Solvency
- BHC has an Altman-Z score of 0.29. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- BHC has a Altman-Z score of 0.29. This is comparable to the rest of the industry: BHC outperforms 46.63% of its industry peers.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- BHC has a better Debt to FCF ratio (21.00) than 76.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.19
WACC6.52%
2.3 Liquidity
- A Current Ratio of 1.47 indicates that BHC should not have too much problems paying its short term obligations.
- BHC has a worse Current ratio (1.47) than 76.68% of its industry peers.
- A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
- BHC has a worse Quick ratio (1.08) than 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. BHC Growth Analysis
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- The Earnings Per Share has been decreasing by -1.13% on average over the past years.
- BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
- BHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.04% yearly.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.34% on average over the next years.
- BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.94% yearly.
EPS Next Y21.76%
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. BHC Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 1.49, the valuation of BHC can be described as very cheap.
- 99.48% of the companies in the same industry are more expensive than BHC, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 26.78. BHC is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 1.22, the valuation of BHC can be described as very cheap.
- 99.48% of the companies in the same industry are more expensive than BHC, based on the Price/Forward Earnings ratio.
- BHC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.54.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.49 | ||
| Fwd PE | 1.22 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 95.34% of the companies listed in the same industry.
- 99.48% of the companies in the same industry are more expensive than BHC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.09 | ||
| EV/EBITDA | 6.37 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BHC has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -5.25% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
5. BHC Dividend Analysis
5.1 Amount
- BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BHC Fundamentals: All Metrics, Ratios and Statistics
5.6
+0.21 (+3.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-29 2026-04-29
Inst Owners44.98%
Inst Owner Change0%
Ins Owners11.09%
Ins Owner Change10.2%
Market Cap2.08B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.37 (31.61%)
Short Float %2.18%
Short Ratio2.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)-0.83%
PT rev (3m)-0.36%
EPS NQ rev (1m)-6.59%
EPS NQ rev (3m)-6.38%
EPS NY rev (1m)5.29%
EPS NY rev (3m)7.09%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)-1.02%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.49 | ||
| Fwd PE | 1.22 | ||
| P/S | 0.2 | ||
| P/FCF | 2.09 | ||
| P/OCF | 1.48 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.37 |
EPS(TTM)3.77
EY67.32%
EPS(NY)4.59
Fwd EY81.97%
FCF(TTM)2.68
FCFY47.85%
OCF(TTM)3.78
OCFY67.47%
SpS27.7
BVpS-1.5
TBVpS-44.44
PEG (NY)0.07
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.52%
ROIC/WACC1.19
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y21.76%
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year34.28%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.11%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
What is the valuation status of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
What is the profitability of BHC stock?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
How financially healthy is BAUSCH HEALTH COS INC?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.
What is the earnings growth outlook for BAUSCH HEALTH COS INC?
The Earnings per Share (EPS) of BAUSCH HEALTH COS INC (BHC) is expected to grow by 21.76% in the next year.